Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.
about
Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis AmesAcetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.The Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected HostRecombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthraxBacillus anthracis Spore Surface Protein BclA Mediates Complement Factor H Binding to Spores and Promotes Spore PersistenceAnthrax vaccines: present status and future prospects.Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.Anthrax Vaccine Precipitated induces Edema Toxin-neutralizing, Edema Factor-specific antibodies in human recipients.Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge with Bacillus cereus G9241.A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis.
P2860
Q28392659-4649838E-1A9F-45CD-BFE3-04C97DA4048BQ36122915-CC98F960-40A7-44BD-9952-51F787B4E300Q36294717-B05C3C28-CDB2-4975-A2F2-B5DD3FC5B195Q36668524-D5998359-281F-4456-9BA2-4F8254C458DEQ37008156-5E8986DA-6842-48FA-AB91-EE532D4B691AQ38132268-7688D101-F4E1-422D-8114-580AFD14C961Q38268596-33F16AED-0C3A-4B12-AB0F-AB96759A781DQ39143157-EC47C061-82CD-4E3E-83A7-45224F71AB2AQ40064017-7A4C299D-0A70-4F0D-8ECD-AD9F6483666BQ46943316-7C8EBCFE-0B8C-4FBF-8E63-DA76973293A2Q54217728-52AEF7C5-F48B-40E3-8D90-0B0207D46B0E
P2860
Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Characterization of a multi-co ...... infection as well as toxaemia.
@ast
Characterization of a multi-co ...... infection as well as toxaemia.
@en
type
label
Characterization of a multi-co ...... infection as well as toxaemia.
@ast
Characterization of a multi-co ...... infection as well as toxaemia.
@en
prefLabel
Characterization of a multi-co ...... infection as well as toxaemia.
@ast
Characterization of a multi-co ...... infection as well as toxaemia.
@en
P2093
P2860
P356
P1476
Characterization of a multi-co ...... infection as well as toxaemia.
@en
P2093
A D Bassett
A D O'Brien
J Reinhardt
S A Tobery
S C Darnell
P2860
P304
P356
10.1099/JMM.0.045393-0
P577
2012-07-05T00:00:00Z